| |
Protein
|
mRNA
|
|---|
| |
Stomach
|
Colon and rectum
|
GC vs. CRC, % difference (p
b)
|
Stomach
|
Colon and rectum
|
GC vs. CRC, % difference (p
b)
|
|---|
|
UIa in paired samples; upregulated pair, n/total pair, n (%)
| |
|
HNRNPA1 or HNRNPA1
|
31/60 (52)
|
106/121 (88)
|
36 (< 0.001)
|
20/45 (44)
|
55/96 (57)
|
13 (0.214)
|
|
SRSF1 or SRSF1
|
13/60 (22)
|
38/121 (31)
|
10 (0.232)
|
17/45 (38)
|
37/96 (39)
|
1 (0.921)
|
|
SRSF3 or SRSF3
|
20/60 (33)
|
89/121 (74)
|
40 (< 0.001)
|
20/45 (44)
|
46/96 (48)
|
3 (0.838)
|
|
SRSF5 or SRSF5
|
15/60 (25)
|
48/121 (40)
|
15 (0.074)
|
16/45 (36)
|
20/96 (21)
|
−15 (0.097)
|
|
SRSF6 or SRSF6
|
17/60 (28)
|
63/121 (52)
|
24 (0.004)
|
16/45 (36)
|
46/96 (48)
|
12 (0.232)
|
|
SRSF7 or SRSF7
|
25/60 (42)
|
69/121 (57)
|
15 (0.115)
|
18/45 (40)
|
45/96 (47)
|
7 (0.559)
|
|
CEA
|
32/60 (53)
|
111/121 (92)
|
38 (< 0.001)
|
–
|
–
|
–
|
|
Detection accuracy, AUC
| | | | | | |
|
Allc (Sensitivity%/Specificity%)
|
n = 147
|
n = 258
| |
n = 111
|
n = 202
| |
|
low-stage ACd
|
n = 127
|
n = 197
| |
n = 95
|
n = 153
| |
|
high-stage ACd
|
n = 103
|
n = 193
| |
n = 78
|
n = 152
| |
|
HNRNPA1 or HNRNPA1
|
0.74 (72/71)
|
0.90e (85/86)
|
17 (< 0.001)
|
0.58e,f (69/50)
|
0.69e,f (54/78)
|
11 (0.117)
|
| |
0.71
|
0.93
|
23 (< 0.001)
|
0.54e
|
0.71e,f
|
17 (0.030)
|
| |
0.77
|
0.89e
|
11 (0.141)
|
0.64e
|
0.64e,f
|
0 (1.000)
|
|
SRSF1 or SRSF1
|
0.58e,f (95/23)
|
0.62e,f (42/82)
|
4 (0.487)
|
0.55e,f (49/65)
|
0.61e,f (88/35)
|
6 (0.399)
|
| |
0.56e
|
0.66e,f
|
10 (0.147)
|
0.53e
|
0.62e,f
|
9 (0.252)
|
| |
0.66e
|
0.58e,f
|
−8 (0.314)
|
0.63e
|
0.58e,f
|
−6 (0.552)
|
|
SRSF3 or SRSF3
|
0.53e,f (53/57)
|
0.84e,f (81/78)
|
32 (<0.001)
|
0.59e,f (71/52)
|
0.65e,f (75/51)
|
7 (0.322)
|
| |
0.56e,f
|
0.84e,f
|
28 (< 0.001)
|
0.54e
|
0.68e,f
|
14 (0.069)
|
| |
0.55e,f
|
0.84e
|
29 (< 0.001)
|
0.60e
|
0.62e,f
|
16 (0.866)
|
|
SRSF5 or SRSF5
|
0.51e,f (60/51)
|
0.62e,f (35/89)
|
11 (0.062)
|
0.52e,f (91/23)
|
0.52e,f (78/38)
|
0 (0.953)
|
| |
0.53e,f
|
0.65e,f
|
12 (0.101)
|
0.54e
|
0.51e,f
|
−3 (0.718)
|
| |
0.62e
|
0.58e,f
|
−3 (0.701)
|
0.53e,f
|
0.54e,f
|
1 (0.914)
|
|
SRSF6 or SRSF6
|
0.61e,f (38/89)
|
0.76e,f (51/96)
|
14 (0.006)
|
0.58e,f (56/62)
|
0.67e,f (60/68)
|
9 (0.192)
|
| |
0.60e
|
0.78e,f
|
18 (0.004)
|
0.53e,f
|
0.68e,f
|
15 (0.062)
|
| |
0.56e,f
|
0.74e,f
|
18 (0.032)
|
0.61e
|
0.65e,f
|
4 (0.699)
|
|
SRSF7 or SRSF7
|
0.63e (30/84)
|
0.74e,f (59/83)
|
11 (0.066)
|
0.54e,f (38/80)
|
0.65e,f (85/43)
|
11 (0.125)
|
| |
0.61e
|
0.75e,f
|
15 (0.036)
|
0.53e
|
0.66e,f
|
12 (0.126)
|
| |
0.71e
|
0.73e,f
|
3 (0.755)
|
0.70e
|
0.64e,f
|
−6 (0.474)
|
|
CEA
|
0.76 (57/89)
|
0.96f (92/94)
|
20 (< 0.001)
|
–
|
–
|
–
|
| |
0.77g
|
0.97
|
20 (< 0.001)
|
–
|
–
|
–
|
| |
0.90g
|
0.99f
|
9 (0.037)
|
–
|
–
|
–
|
-
Abbreviations: AC adenocarcinoma, AUC area under the curve, CEA carcinoembryonic antigen, CRC colorectal cancer, GC gastric cancer, NM normal mucosa, UI upregulation incidence
-
aUIs in cancer were acquired using paired samples from the same patient (cancer/NM >2-fold)
-
b
p value was acquired by chi-square test
-
cAUCs were acquired for all types of cancer (including non-AC), regardless of TNM stage
-
dAUCs were acquired for low-stage AC (TNM stage I/II AC) or for high-stage AC (TNM stage III/IV AC)
-
e
p < 0.05: compared with the respective AUC of CEA; p values for the paired AUC were acquired by the DeLong test
-
f
p < 0.05: compared with the respective AUC of HNRNPA1; p values for the paired AUC acquired by the DeLong test
-
g
p < 0.05: AUC of low-stage AC vs. AUC of high-stage AC; p values were acquired by independent receiver operating characteristic curve comparison test
